The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers
A Randomized Placebo Controlled Double Blind Two Period Cross-Over Study to Assess the Safety and Pharmacokinetics and Pharmacodynamics of Oral Dosages of TRIA-662 (A Hypolipidemic Agent) in Healthy Volunteers
Sponsor: Cortria Corporation
A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Cortria Corporation and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cortria Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.